A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.
about
Ocular itch associated with allergic conjunctivitis: latest evidence and clinical managementTherapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvementTacrolimus (FK506) suppresses TREM-1 expression at an early but not at a late stage in a murine model of fungal keratitisUpdates in the treatment of ocular allergies.Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitisRecent patents and emerging therapeutics in the treatment of allergic conjunctivitis.Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitisTacrolimus Ointment for Treatment of Vernal Keratoconjunctivitis.Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis.A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host DiseaseTreatment of refractory dry eye associated with graft versus host disease with 0.03% tacrolimus eyedrops.Tacrolimus in the treatment of ocular diseases.Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes.Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis.Phase II drugs under investigation for allergic conjunctivitis.Advances in pharmacotherapy for allergic conjunctivitis.An Update on the Therapeutic Approach to Vernal Keratoconjunctivitis.Therapeutic effect of 0.1% Tacrolimus Eye Ointment in Allergic Ocular Diseases.Topical tacrolimus in anterior segment inflammatory disorders.Topical 0.03% tacrolimus for subepithelial infiltrates secondary to adenoviral keratoconjunctivitis.Management of vernal keratoconjunctivitis.Long-term use of 0.003% tacrolimus suspension for treatment of vernal keratoconjunctivitis.Treatment of atopic keratoconjunctivitis in patients with atopic dermatitis: is ocular application of tacrolimus an option?Tacrolimus vs. cyclosporine eyedrops in severe cyclosporine-resistant vernal keratoconjunctivitis: A randomized, comparative, double-blind, crossover study.Relation between total tear IgE and severity of acute seasonal allergic conjunctivitis.Specific IgE in tear fluid and features of allergic conjunctivitis.The efficacy of topical interferon alpha 2b treatment in refractory vernal keratoconjunctivitis.Modulation of postoperative scarring with tacrolimus and octreotide in experimental glaucoma filtration surgery.The role of Staphylococcal enterotoxin in atopic keratoconjunctivitis and corneal ulceration.
P2860
Q26771818-689D1795-5B12-459C-91E9-4681A1763CB2Q33956479-06A05DDE-0966-4C0C-8D1A-2ABF45313554Q34612464-D0FDBBD1-BA8E-4098-8307-0123E0AD34A1Q34620159-B8F2A581-54DE-4B26-A8E3-1150A5534886Q34882570-80D303D1-2460-4CF6-A4D7-28D28232A550Q35187578-01E4BACA-FF86-4E8B-AA49-69D090375629Q35226825-08B5F51D-30C5-43AD-BAEF-66645857CFEBQ36596448-EAA1A4C6-15AE-4F71-A863-25E67F90A38BQ36787750-61A5CA10-384D-4D1D-B927-B3CF39A02756Q37038747-269A6A98-0E2D-4531-ABF6-249118608C10Q37208060-935BBF98-B76C-4A76-AB6E-C2E985DC1B3DQ37858514-798FCD43-B0A8-43CA-A45B-3EF84680CE2BQ38179488-53F6D121-4F65-4BB6-A2B2-3BA0CAA43947Q38184630-4C682F2F-27E7-4760-802D-959158369659Q38234039-030369E8-5B3A-462A-9D12-92E5880CEBFDQ38460976-7FB4CECE-C37D-4011-ACFF-2B32090D9B0CQ38909557-70BCCBB2-0213-4ACA-A06A-232FA0DE34F9Q39168929-8B71D85B-788E-4D83-A7C7-3363C44F7E30Q39175604-11DACCA6-8F93-4615-BB79-339CDA1F87CEQ42227310-FFE6E3B7-72B5-4801-9753-CD1933A676B5Q42745061-4A351435-10E2-496A-AF47-4B87161E8278Q46046521-94D99283-A679-492B-838B-FACB8B282975Q46957199-C8A7A72B-0F94-429D-962D-2678AB827E2AQ48048235-CA80E5D8-61C3-4288-974F-4EEF7ED305F0Q49188504-9F9909E6-3600-47F1-A192-9C4238F36813Q50955853-7F31DB2E-37C5-4F6C-A7B4-A10916B94CC7Q51353842-E1179D0F-9359-41C9-979F-9E746D92E784Q53185510-35562A17-AD83-4344-B108-2868538D6CF3Q54315649-3C0209CD-4F4E-48EE-A92A-6EBFD2E5A45A
P2860
A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A randomized, placebo-controll ...... evere allergic conjunctivitis.
@ast
A randomized, placebo-controll ...... evere allergic conjunctivitis.
@en
type
label
A randomized, placebo-controll ...... evere allergic conjunctivitis.
@ast
A randomized, placebo-controll ...... evere allergic conjunctivitis.
@en
prefLabel
A randomized, placebo-controll ...... evere allergic conjunctivitis.
@ast
A randomized, placebo-controll ...... evere allergic conjunctivitis.
@en
P2093
P2860
P356
P1476
A randomized, placebo-controll ...... evere allergic conjunctivitis.
@en
P2093
Atsuki Fukushima
Etsuko Takamura
Hiroshi Fujishima
Kenichi Namba
Kunihiko Hayashi
Naoki Kumagai
Nobuyuki Ebihara
Shigeki Okamoto
Yayoi Nakagawa
P2860
P304
P356
10.1089/JOP.2009.0087
P577
2010-04-01T00:00:00Z